This project related to the Neonatal Research Network INS-3 protocol. The INS-3 was a phase 3, randomized, double-masked, placebo-controlled study designed to determine the effectiveness of myo-Inositol 5% Injection to increase survival in premature infants <28 0/7 weeks' gestation. Following this trial, RTI International supported the preparation of the Clinical Study Report (CSR). This support included retrieving, assessing, assembling, and reporting information generated by the Eunice Kennedy Shriver National Institute of Child Health and Human Development or by RTI during the course of the study that was relevant to the CSRs.